JP2025514066A5 - - Google Patents

Info

Publication number
JP2025514066A5
JP2025514066A5 JP2024561794A JP2024561794A JP2025514066A5 JP 2025514066 A5 JP2025514066 A5 JP 2025514066A5 JP 2024561794 A JP2024561794 A JP 2024561794A JP 2024561794 A JP2024561794 A JP 2024561794A JP 2025514066 A5 JP2025514066 A5 JP 2025514066A5
Authority
JP
Japan
Prior art keywords
compound
chemical formula
adduct
crystalline form
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514066A (ja
Filing date
Publication date
Priority claimed from CN202210409814.5A external-priority patent/CN114634489B/zh
Application filed filed Critical
Publication of JP2025514066A publication Critical patent/JP2025514066A/ja
Publication of JP2025514066A5 publication Critical patent/JP2025514066A5/ja
Pending legal-status Critical Current

Links

JP2024561794A 2022-04-19 2022-05-04 結晶形 Pending JP2025514066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210409814.5A CN114634489B (zh) 2022-04-19 2022-04-19 结晶形式
CN202210409814.5 2022-04-19
PCT/EP2022/062061 WO2023202787A1 (en) 2022-04-19 2022-05-04 Crystalline forms

Publications (2)

Publication Number Publication Date
JP2025514066A JP2025514066A (ja) 2025-05-02
JP2025514066A5 true JP2025514066A5 (https=) 2025-05-13

Family

ID=81940491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561794A Pending JP2025514066A (ja) 2022-04-19 2022-05-04 結晶形

Country Status (6)

Country Link
US (1) US20260070895A1 (https=)
EP (1) EP4511124A1 (https=)
JP (1) JP2025514066A (https=)
CN (1) CN114634489B (https=)
TW (1) TWI850657B (https=)
WO (1) WO2023202787A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
AR053046A1 (es) * 2005-04-07 2007-04-18 Teijin Pharma Ltd Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo
EP2305643A1 (en) 2009-10-02 2011-04-06 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers
EP3327007B1 (en) * 2015-07-24 2020-06-03 Shenzhen Zhenxing Medical Technology Co., Ltd. Orbit azine-fumarate, hydrate, crystal form and preparation method therefor
CN107759600A (zh) * 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
EP3318256A1 (en) 2016-11-08 2018-05-09 Quimatryx, S.L Compounds for the treatment of autoimmune diseases
AU2020259100B2 (en) * 2019-04-17 2024-12-12 Fundación Kertor 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors

Similar Documents

Publication Publication Date Title
JP2025114615A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
JP2017082007A (ja) ｃ−Ｍｅｔモジュレーターの使用方法
JP2022541749A5 (https=)
JP7446460B2 (ja) 新規ｅｐ４拮抗薬の合成及びその癌及び炎症における使用
EP3992176A1 (en) Ep2 antagonist
JP7838842B2 (ja) 病的状態の治療における使用のための芳香族分子
JP2025510438A (ja) 重水素化複素環ケトン類化合物及びその使用
JP2021534215A (ja) 病的症状の治療における使用のための芳香族分子
JP2017532377A (ja) インドリノン化合物及びその使用
CN115894379A (zh) 海因类化合物及其医药用途
JP2025514066A5 (https=)
CN108884099B (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
JP2025111455A (ja) 抗増殖活性を有するフェノキシ（ヘテロ）アリールエーテル
JP2018515540A (ja) 乳癌の予防又は治療用の化合物
JP7807487B2 (ja) 新規の芳香族化合物
CN108473449B (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的砜脒及其制备方法和用途
CN113024422A (zh) 丁苯酞开环化合物、药物化合物以及它们的制备方法、组合物和应用
JP7223842B2 (ja) 選択的ａ２ａ受容体アンタゴニスト
JP2023539639A (ja) Ｓｓａｏ阻害剤の多形
CN107849020A (zh) 一种舒尼替尼前药及药物组合物
CN113549046B (zh) 一种双联苄地钱素s衍生物及其制备方法和应用
CN115286574B (zh) Blvrb酶功能抑制剂及其制备方法和用途
CN118406058A (zh) 一种替莫唑胺-阿魏酸的药物共晶体及其制备方法
CN108349882B (zh) 一种取代的丙烯酰胺化合物及其药物组合物
TW202506646A (zh) ３－（５，７－二氟－４－側氧基－１，４－二氫喹啉－２－基）－４－（甲基磺醯基）苯甲腈的結晶型